PHX — Pharmx Technologies Income Statement
0.000.00%
Last trade - 00:00- AU$45.49m
- AU$41.19m
- AU$6.78m
- 89
- 48
- 95
- 89
Annual income statement for Pharmx Technologies, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | R2021 June 30th | R2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.6 | 11.9 | 5.38 | 6.13 | 6.78 |
| Cost of Revenue | |||||
| Gross Profit | 9.44 | 10.3 | 4.56 | 4.92 | 5.55 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 11.9 | 12.1 | 5.26 | 6.79 | 6.54 |
| Operating Profit | -1.27 | -0.247 | 0.127 | -0.665 | 0.244 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 0.458 | 1.35 | 0.122 | -0.719 | 0.201 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 0.176 | 1.08 | -0.131 | -0.883 | 0.095 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 0.176 | 1.09 | 0.252 | -1.05 | -1.77 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 0.176 | 1.09 | 0.252 | -1.05 | -1.77 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.003 | 0.002 | -0 | -0.001 | -0.001 |
| Special Dividends per Share |